Halozyme starts Phase Ib/II of PEGPH20 plus Tecentriq

In October, Halozyme Therapeutics Inc. (NASDAQ:HALO) began the Phase Ib/II HALO-110-101 trial to evaluate PEGPH20 in combination with standard

Read the full 194 word article

User Sign In